0001558370-24-002314.txt : 20240304 0001558370-24-002314.hdr.sgml : 20240304 20240304073051 ACCESSION NUMBER: 0001558370-24-002314 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240304 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240304 DATE AS OF CHANGE: 20240304 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HELIUS MEDICAL TECHNOLOGIES, INC. CENTRAL INDEX KEY: 0001610853 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 364787690 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38445 FILM NUMBER: 24712855 BUSINESS ADDRESS: STREET 1: 642 NEWTOWN YARDLEY ROAD CITY: NEWTOWN STATE: PA ZIP: 18940 BUSINESS PHONE: 215-944-6100 MAIL ADDRESS: STREET 1: 642 NEWTOWN YARDLEY ROAD CITY: NEWTOWN STATE: PA ZIP: 18940 FORMER COMPANY: FORMER CONFORMED NAME: HELIUS MEDICAL TECHNOLOGIES, INC DATE OF NAME CHANGE: 20180517 FORMER COMPANY: FORMER CONFORMED NAME: HELIUS MEDICAL TECHNOLOGIES, INC. DATE OF NAME CHANGE: 20140613 8-K 1 hsdt-20240304x8k.htm 8-K
0001610853falseDE00016108532024-03-042024-03-04

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 4, 2024

Graphic

HELIUS MEDICAL TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

​

-

​

​

Delaware

001-38445

36-4787690

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

​

​

​

642 Newtown Yardley Road, Suite 100

Newtown, PA

 

18940

(Address of principal executive offices)

 

(Zip Code)

​

Registrant’s telephone number, including area code: (215) 944-6100

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

​

​

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​

​

​

​

​

​

Title of each class

    

Trading

Symbol(s)

    

Name of each exchange on which registered

Class A Common Stock, $0.001 par value

​

HSDT

​

The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

Item 8.01

Other Events

On March 4, 2024, Helius Medical Technologies, Inc. (the “Company”) issued a press release announcing that the Centers for Medicare & Medicaid Services (CMS) has assigned Healthcare Common Procedure Coding System (HCPCS) Level II codes to the PoNS controller and PoNS mouthpiece, effective April 1, 2024. In addition, the Company plans to provide CMS additional information to support reimbursement economics ahead of the public meetings expected early this summer and believes there is a reasonable expectation that CMS will then determine a reimbursement amount for each of the PoNS controller and mouthpiece to be effective October 1, 2024.

​

A press release issued by the Company on March 4, 2024 regarding the assignment of these HCPCS codes is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. 

​

Cautionary Disclaimer Statement

​

Certain statements in this Current Report on Form 8-K are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believe,” “expect,” “continue,” “will,” “goal,” “aim” and similar expressions. Such forward-looking statements include, among others, the Company’s plans to provide CMS additional information to support reimbursement economics ahead of the public meetings expected early this summer and the expectation that CMS will then determine a reimbursement amount for each of the PoNS controller and mouthpiece to be effective October 1, 2024.

​

There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties associated with the Company’s capital requirements to achieve its business objectives, disruptions in the banking system and financial markets, the effect of macroeconomic conditions and the Company’s ability to access capital markets, the Company’s ability to continue to train physical therapists in the supervision of the use of the PoNS Treatment, the Company’s ability to secure additional contracts with rehabilitation clinics, the Company’s ability to obtain national Medicare coverage and to obtain a reimbursement code so that the PoNS device is covered by Medicare and Medicaid, the Company’s ability to build internal commercial infrastructure, secure state distribution licenses, build a commercial team and build relationships with Key Opinion Leaders, neurology experts and neurorehabilitation centers, market awareness of the PoNS device, availability of funds, manufacturing, labor shortage and supply chain risks, our ability to maintain and enforce our intellectual property rights, clinical trials and the clinical development process, the product development process, the regulatory submission review and approval process, our operating costs and use of cash, and our ability to achieve significant revenues, ongoing government regulation, and other risks detailed from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.

​

The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.

​

​

1

Item 9.01 Financial Statements and Exhibits.

​

(d)

Exhibits:

​

 

Exhibit
No.

 

Description

 

 

 

99.1

 

Press release, dated March 4, 2024

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

​

​

​

​

​

​

​

​

​

2

​

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

​

​

​

​

​

HELIUS MEDICAL TECHNOLOGIES, INC.

​

​

​

​

Dated: March 4, 2024

​

By:

/s/ Jeffrey S. Mathiesen

​

​

​

Jeffrey S. Mathiesen

​

​

​

Chief Financial Officer, Treasurer and Secretary

​

​

​

​

3

 EX-99.1 2 hsdt-20240304xex99d1.htm EX-99.1

Exhibit 99.1

Graphic

​

Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller

-- Significant step toward reimbursement for the only medical device approved in the U.S. for treatment of gait deficit due to multiple sclerosis (“MS”) --

-- Proceeds from recent stock issuances through the Company’s At-The-Market (“ATM”) program extends cash runway into the third quarter 2024 –

​

NEWTOWN, Pa., March 4, 2024 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Centers for Medicare & Medicaid Services (“CMS”) has assigned Healthcare Common Procedure Coding System (“HCPCS”) Level II codes A4593, “Neuromodulation stimulator system, adjunct to rehabilitation therapy regime” to describe the PoNS controller and A4594, “Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece each” to describe the PoNS mouthpiece. The new HCPCS codes will be effective April 1, 2024.

“PoNS Therapy® is life-changing for people who suffer gait impairment due to MS and we’re pleased that CMS understood the benefits of this innovative treatment by establishing HCPCS codes for both the PoNS mouthpiece and controller. This marks a critical reimbursement and access milestone and provides Helius the ability to begin negotiating reimbursement with third-party payers using these unique HCPCS codes. We believe there is a reasonable likelihood that at the public meetings this summer CMS will determine a reimbursement amount for each of the PoNS controller and mouthpiece to take effect on October 1, 2024,” stated Helius’ President and Chief Executive Officer, Dane Andreeff.

“As we pursue widespread reimbursement for PoNS Therapy, we have continued to manage our cash burn. With the recently announced $1.5 million of net proceeds from the sale of shares of our common stock under our ATM program at an average share price of $9.17 per share, our cash runway has been extended into the third quarter of this year. Once we establish reimbursement for PoNS, we believe we will be able to expand reimbursement across third-party payers and have a pathway to positive cash flow as we continue to pursue authorization for stroke in the U.S.,” concluded Andreeff.

PoNS is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from MS and is to be used as an adjunct to a supervised therapeutic exercise program. The Company is also seeking marketing authorization under PoNS’s breakthrough designation for stroke in the United States, where over five million stroke survivors are affected by walking and balance disability. In Canada, PoNS is authorized to treat balance impairment due to MS, stroke and mild-to-moderate traumatic brain injury.

1

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator. For more information visit www.heliusmedical.com.

About the PoNS Device and PoNS Therapy

The Portable Neuromodulation Stimulator (PoNS) is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a controller and it’s used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.

​

PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications: (i) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke and is to be used in conjunction with physical therapy; (ii) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit www.ponstherapy.com.

Cautionary Disclaimer Statement

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believe,” “expect,” “continue,” “will,” “goal,” “aim” and similar expressions. Such forward-looking statements include, among others, statements regarding the Company’s plans to provide CMS additional information to support reimbursement economics ahead of the public meetings expected early this summer and the expectation that CMS will then determine a reimbursement amount for each of the PoNS controller and mouthpiece to be effective October 1, 2024, the success of the Company’s developmental, regulatory and commercialization efforts, the impact of HCPCS codes on the Company’s commercialization efforts, the sufficiency of the Company’s future cash position, future decisions and approvals from applicable regulatory entities in the U.S. and Canada, and the uses and effectiveness of PoNS and PoNS Therapy.

​

There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties

2

associated with the Company’s capital requirements to achieve its business objectives, disruptions in the banking system and financial markets, the effect of macroeconomic conditions and the Company’s ability to access capital markets, the Company’s ability to continue to train physical therapists in the supervision of the use of the PoNS Treatment, the Company’s ability to secure additional contracts with rehabilitation clinics, the Company’s ability to obtain national Medicare coverage and to obtain a reimbursement code so that the PoNS device is covered by Medicare and Medicaid, the Company’s ability to build internal commercial infrastructure, secure state distribution licenses, build a commercial team and build relationships with Key Opinion Leaders, neurology experts and neurorehabilitation centers, market awareness of the PoNS device, availability of funds, manufacturing, labor shortage and supply chain risks, our ability to maintain and enforce our intellectual property rights, clinical trials and the clinical development process, the product development process, the regulatory submission review and approval process, our operating costs and use of cash, and our ability to achieve significant revenues, ongoing government regulation, and other risks detailed from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.

​

The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.

​

Investor Relations Contact

Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

3

 GRAPHIC 3 hsdt-20240304x8k001.jpg GRAPHIC begin 644 hsdt-20240304x8k001.jpg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end GRAPHIC 4 hsdt-20240304xex99d1001.jpg GRAPHIC begin 644 hsdt-20240304xex99d1001.jpg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hsdt-20240304.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 hsdt-20240304_lab.xml EX-101.LAB EX-101.PRE 7 hsdt-20240304_pre.xml EX-101.PRE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Mar. 04, 2024
Document and Entity Information [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 04, 2024
Entity Registrant Name HELIUS MEDICAL TECHNOLOGIES, INC.
Entity Central Index Key 0001610853
Entity Emerging Growth Company false
Entity File Number 001-38445
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 36-4787690
Entity Address, Address Line One 642 Newtown Yardley Road
Entity Address, Adress Line Two Suite 100
Entity Address, City or Town Newtown
Entity Address State Or Province PA
Entity Address, Postal Zip Code 18940
City Area Code (215)
Local Phone Number 944-6100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, $0.001 par value
Trading Symbol HSDT
Security Exchange Name NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports hsdt-20240304.xsd hsdt-20240304_lab.xml hsdt-20240304_pre.xml hsdt-20240304x8k.htm hsdt-20240304x8k001.jpg http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hsdt-20240304x8k.htm": { "nsprefix": "hsdt", "nsuri": "http://www.heliusmedical.com/20240304", "dts": { "schema": { "local": [ "hsdt-20240304.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "hsdt-20240304_lab.xml" ] }, "presentationLink": { "local": [ "hsdt-20240304_pre.xml" ] }, "inline": { "local": [ "hsdt-20240304x8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_3_4_2024_To_3_4_2024_ysegKCUFu0Klq1FZpgiQwA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hsdt-20240304x8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_3_4_2024_To_3_4_2024_ysegKCUFu0Klq1FZpgiQwA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hsdt-20240304x8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Adress Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0001558370-24-002314-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-002314-xbrl.zip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hsdt-20240304x8k_htm.xml IDEA: XBRL DOCUMENT 0001610853 2024-03-04 2024-03-04 0001610853 false DE 8-K 2024-03-04 HELIUS MEDICAL TECHNOLOGIES, INC. 001-38445 36-4787690 642 Newtown Yardley Road Suite 100 Newtown PA 18940 (215) 944-6100 false false false false Class A Common Stock, $0.001 par value HSDT NASDAQ false